PROTAGONIST THERAPEUTICS INC. overview
PROTAGONIST THERAPEUTICS INC.
> News
ACCESSWIRE published a news.
Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year
•
•
ACCESSWIRE •
Stocks •
More PROTAGONIST THERAPEUTICS INC. news...
Thank you
Chart
Statistics
- Analyses : 2
- Followers : 2